Milestone Pharmaceuticals (NASDAQ:MIST) Rating Increased to Hold at Zacks Research

Milestone Pharmaceuticals (NASDAQ:MIST) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report released on Monday,Zacks.com reports.

Several other analysts also recently commented on MIST. Raymond James Financial initiated coverage on shares of Milestone Pharmaceuticals in a research report on Friday, April 10th. They issued a “strong-buy” rating and a $6.00 target price for the company. Wall Street Zen lowered Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th. Finally, Wells Fargo & Company dropped their price target on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating on the stock in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $7.25.

Milestone Pharmaceuticals Price Performance

Milestone Pharmaceuticals stock opened at $1.30 on Monday. Milestone Pharmaceuticals has a 1 year low of $1.00 and a 1 year high of $3.06. The firm has a 50 day moving average price of $1.40 and a 200 day moving average price of $1.66. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.09 and a current ratio of 9.18. The company has a market cap of $161.85 million, a price-to-earnings ratio of -1.91 and a beta of 0.97.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.26). The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $30.11 million. Sell-side analysts predict that Milestone Pharmaceuticals will post -0.97 earnings per share for the current year.

Insider Buying and Selling at Milestone Pharmaceuticals

In other news, CEO Joseph Oliveto sold 36,500 shares of the stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $2.26, for a total value of $82,490.00. Following the sale, the chief executive officer owned 446,244 shares of the company’s stock, valued at approximately $1,008,511.44. This represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.03% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MIST. Seven Fleet Capital Management LP purchased a new position in shares of Milestone Pharmaceuticals during the first quarter worth about $397,000. Renaissance Technologies LLC purchased a new position in Milestone Pharmaceuticals in the 1st quarter valued at about $154,000. Welch & Forbes LLC acquired a new position in Milestone Pharmaceuticals during the 1st quarter worth $30,000. Invesco Ltd. bought a new position in Milestone Pharmaceuticals in the 4th quarter worth about $44,000. Finally, Cetera Investment Advisers bought a new stake in Milestone Pharmaceuticals during the fourth quarter worth approximately $42,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.